Related Experiment Videos
Current therapy of refractory multiple myeloma
1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048-1869, USA.
Stem Cells (Dayton, Ohio)
|August 1, 1995
Summary
Standard multiple myeloma (MM) induction therapy offers limited long-term remission, with many patients experiencing relapse or primary resistance. Research is exploring new strategies to overcome drug resistance in MM patients.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Standard induction therapy for multiple myeloma (MM) yields objective response rates of 40%-50% in previously untreated patients.
- Most patients achieving initial remission eventually relapse, with less than 20% in ongoing remission at five years.
- Approximately 30% of MM patients inadequately respond to induction chemotherapy, facing disease progression or refractory symptoms.
Purpose of the Study:
- To address the lack of agreed terminology for relapsed and resistant multiple myeloma.
- To review recent data on cytotoxic and/or systemic radiation therapy for refractory MM.
- To explore strategies for overcoming drug resistance in multiple myeloma.
Main Methods:
- Review of existing literature on multiple myeloma induction therapy outcomes.
- Analysis of patient response rates and progression patterns.
- Examination of emerging research on drug resistance mechanisms and therapeutic interventions.
Main Results:
- Standard regimens achieve moderate initial response but poor long-term remission rates in multiple myeloma.
- A significant proportion of patients are classified as nonresponders, including those with primary resistance or slow responses.
- Prolongation of median survival in refractory MM patients remains a significant challenge.
Conclusions:
- Current cytotoxic therapies for multiple myeloma have limitations in achieving durable responses and overcoming resistance.
- Standardized classification of relapsed and resistant disease is crucial for clinical study planning and data interpretation.
- Further investigation into drug resistance mechanisms and novel therapeutic approaches is essential to improve outcomes for refractory multiple myeloma patients.